Kwangdong clinical study approved for KD501, Arzheimer drug.

Kwangdong announced on July 23 that a clinical phase II study protocol for KD501, an Arzheimer disease therapy of natural origin, was approved by the KFDA.

KD501 is a new anti-psychotic drug with natural origin jointly developed by Kwangdong Research teams in association with Prof. Kim Young-joong of SNU College of Pharmacy and Welcome Science, a natural drug research venture company. Its p...